Brainsway (BWAY) has released an update.
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, has announced promising review results for its Deep TMS treatment as a potential therapy for Parkinson’s Disease. Clinical trials involving 220 patients showed significant improvements in motor and non-motor symptoms, with severe cases responding particularly well, although Deep TMS is not yet FDA-approved for Parkinson’s. BrainsWay’s innovative two-stage H-Coil protocol could offer benefits like improved cognitive function and quality of life, with fewer side effects than traditional drugs.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
